Request an invite

Itvisma: how long were the pivotal tox studies?

onasemnogene abeparvovec (intrathecal) · SMN1 (AAV9, intrathecal)
Longest pivotal study
52 weeks
“These studies demonstrated that OAV101 was well tolerated at this dose level up to 12 months post injection, with minor microscopic findings reported 6 weeks post-administration in the dorsal root ganglia (DRG), spinal cord, peripheral nerves, and brain that did not increase in severity or incidence over the 12 month study.”
✓ VerifiedFDA summary basis for approval, p. 15Source ↗
Pivotal GLP studies
Single-dose IT NHP study (1.2, 3.0, 6.0 x10^13 vg/animal) to 12 months; mouse ICV studies; IV mouse FEED and EFD
“A single IT dose of onasemnogene abeparvovec was administered at three dose levels: 1.20 × 10 13 vg/animal (equivalent to the clinical therapeutic dose), 3.0 × 10 13 vg/animal, and 6.0 × 10 13 vg/animal.”
✓ VerifiedUS prescribing informationSource ↗
Route in tox
Intrathecal (NHP); intracerebroventricular (neonatal mice); intravenous (mouse fertility/EFD)
“Additional single-dose studies in the newborn Friend Virus B (FVB) mouse strain and NHPs further demonstrated high tolerability to OAV101 or scAAV9.CBA.SMN following ICV or IT administration, respectively, with no major safety signals.”
✓ VerifiedFDA summary basis for approval, p. 16Source ↗

Same question, other gene therapies

Adstiladrin

nadofaragene firadenovec · IFN-alpha2b (adenovirus, intravesical)
22 (derived from the dosing and observation schedule)

Beqvez

fidanacogene elaparvovec · Factor IX
104 weeks

Casgevy

exagamglogene autotemcel · BCL11A enhancer (CRISPR-Cas9, ex vivo HSC)
20 weeks

Elevidys

delandistrogene moxeparvovec · Micro-dystrophin
24 weeks

Fayuvi

rebisufligene etisparvovec · SGSH (AAV9)
26 weeks

Genglycos

pariglasgene brecaparvovec · G6PC (AAV8)
26 weeks

Glybera

alipogene tiparvovec · LPL (AAV1)
26 weeks

Hemgenix

etranacogene dezaparvovec · Factor IX
26 weeks

Imlygic

talimogene laherparepvec · GM-CSF (oncolytic HSV-1)
12 (derived from the dosing and observation schedule)

Kebilidi

eladocagene exuparvovec · AADC
26 weeks

Kresladi

marnetegragene autotemcel · ITGB2 (LVV, ex vivo HSC)
4 weeks

Lenmeldy

atidarsagene autotemcel · ARSA (LVV, ex vivo HSC)
52 weeks

Luxturna

voretigene neparvovec · RPE65
31 weeks

Lyfgenia

lovotibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)
26 weeks

Otarmeni

lunsotogene parvec · OTOF (AAV, intracochlear)
27 weeks

Papzimeos

zopapogene imadenovec · HPV6/11 antigens (gorilla adenovirus)
3 weeks

Roctavian

valoctocogene roxaparvovec · Factor VIII
26 weeks

Skysona

elivaldogene autotemcel · ABCD1 (LVV, ex vivo HSC)
13 (derived from the dosing and observation schedule)

Strimvelis

autologous CD34+ cells transduced with ADA (no INN) · ADA (gamma-retroviral, ex vivo HSC)
16 weeks

Tudriqev

vusolimogene oderparepvec · GALV-GP + GM-CSF (oncolytic HSV-1)
26 weeks

Vyjuvek

beremagene geperpavec · COL7A1 (HSV-1, topical)
9 (derived from the dosing and observation schedule)

Waskyra

etuvetidigene autotemcel · WAS (LVV, ex vivo HSC)
64 weeks

Zevaskyn

prademagene zamikeracel · COL7A1 (RV-modified keratinocyte sheets)
8 weeks

Zolgensma

onasemnogene abeparvovec · SMN1
26 weeks

Zynteglo

betibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)
26 weeks

Summary across all 26 gene therapies →